The latest price target for Cue Biopharma (NASDAQ:CUE) was reported by Stifel on August 20, 2024. The analyst firm set a price target for $4.00 expecting CUE to rise to within 12 months (a possible 175.86% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Cue Biopharma (NASDAQ:CUE) was provided by Stifel, and Cue Biopharma maintained their buy rating.

There is no last upgrade for Cue Biopharma

There is no last downgrade for Cue Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cue Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cue Biopharma was filed on August 20, 2024 so you should expect the next rating to be made available sometime around August 20, 2025.

While ratings are subjective and will change, the latest Cue Biopharma (CUE) rating was a maintained with a price target of $8.00 to $4.00. The current price Cue Biopharma (CUE) is trading at is $1.45, which is out of the analyst’s predicted range.